The global Alzheimer’s therapeutics market is projected to grow from US$ 4.3 billion in 2026 to US$ 10.4 billion by 2036, expanding at a CAGR of 9.3% during the forecast period. According to Future Market Insights (FMI), the market is entering a transformative phase as healthcare systems worldwide shift from symptomatic management toward disease-modifying therapies and precision neurology solutions.
Recent FDA approvals of anti-amyloid therapies such as lecanemab and donanemab are fundamentally reshaping the Alzheimer’s treatment landscape. These next-generation biologics are creating the first realistic pathway toward slowing disease progression rather than merely masking symptoms. Simultaneously, the growing burden of dementia globally is accelerating investments in diagnostic infrastructure, infusion centres, biomarker testing, and long-term neurological care delivery systems.
Get detailed market forecasts, competitive benchmarking, and pricing trends from future market insights.
Market drivers and strategic shifts
The rapid evolution of the Alzheimer’s therapeutics market is closely linked to rising global aging populations, increasing dementia prevalence, and growing demand for therapies capable of slowing neurodegeneration. Healthcare systems are increasingly prioritising early diagnosis, biomarker-driven treatment pathways, and outpatient neurological care models to reduce long-term institutionalisation costs.
According to the Alzheimer’s Association 2025 report, over seven million Americans are currently living with Alzheimer’s disease, with the figure projected to nearly double by 2050. This escalating burden is driving significant investments in infusion infrastructure, hospital pharmacy networks, and diagnostic screening programmes.
Key growth drivers include:
• Rising adoption of disease-modifying anti-amyloid therapies
• Expansion of biomarker-based early diagnosis platforms
• Growing investments in infusion centres and neurological care infrastructure
• Increasing demand for home-based and outpatient dementia management
• Strong clinical pipeline activity targeting tau proteins, inflammation, and metabolic dysfunction
• Rising awareness and diagnosis rates across emerging economies
• Growing integration of blood-based biomarker testing technologies.
However, the market continues to face challenges including high treatment costs, reimbursement complexities, safety monitoring requirements, and the historically high failure rate of Alzheimer’s clinical trials.
Segment and regional insights
Donepezil is expected to dominate the drug category, accounting for 67.7% market share in 2026 due to its established safety profile, oral administration convenience, and continued use as the first-line symptomatic treatment across all stages of Alzheimer’s disease.
Hospital pharmacies will continue leading the distribution channel segment with a 35.0% share, supported by the increasing adoption of infusion-based biologics requiring clinical supervision, MRI monitoring, and specialised patient management infrastructure.
Regional data includes:
• Japan is emerging as a leading growth market driven by its rapidly aging population and supportive reimbursement environment
• India is witnessing strong expansion through improving healthcare access and rising neurodegenerative disease awareness
• The United States remains focused on biologics innovation, biomarker integration, and infusion network expansion
• Germany is strengthening early-stage diagnostic infrastructure and reimbursement frameworks
• The United Kingdom is leveraging NHS-backed clinical research ecosystems and real-world evidence generation.
Countries such as Japan, India, the USA, Germany, and the UK are driving both commercialisation and technological innovation in Alzheimer’s therapeutics.
Competitive landscape
The market is characterised by aggressive R&D investments, strategic licensing partnerships, and growing competition in disease-modifying immunotherapies. Leading pharmaceutical companies are focusing on expanding neurodegenerative pipelines while integrating diagnostics, biologics manufacturing, and precision medicine capabilities.
Key players include Eisai Co, Novartis AG, AbbVie, Biogen, Eli Lilly and Company, Aurobindo Pharma, Johnson & Johnson, Dr Reddy’s Laboratories, Viatris and F Hoffmann-La Roche.
Competitive strategies are increasingly centred on:
• Expansion of anti-amyloid immunotherapy portfolios
• Development of multi-mechanism neurological therapies
• Integration of blood-based biomarker diagnostics
• Strategic collaborations with diagnostic technology firms
• Investment in infusion infrastructure and specialty pharmacy networks
• Focus on health economic value and reimbursement optimisation
• Outsourcing manufacturing to CDMOs for scalability and cost efficiency.
